Canada to cover cost of contraception and diabetes drugs
Canada's parliament approved a bill to cover contraception and diabetes medication costs, increasing federal spending by C$1.9 billion over five years, despite potential opt-outs from Alberta and Quebec.
Read original article
Canada's parliament has approved a bill to fully cover the costs of contraception and diabetes medications for Canadians, marking a significant step towards a publicly funded national pharmacare program. The Liberal government estimates that one in five Canadians struggle to afford prescription drugs, and the new program aims to alleviate this burden. The bill is projected to increase federal spending by C$1.9 billion over the next five years. It will provide coverage for diabetes medications, including insulin and Metformin, and contraception options for approximately nine million women of reproductive age. Prime Minister Justin Trudeau described the bill's passage as "real progress" and encouraged provinces to expedite agreements for implementation. However, Alberta and Quebec have expressed intentions to opt-out, citing concerns over federal overreach. The legislation is a result of a deal between the minority Liberals and the New Democratic Party (NDP), which has since withdrawn its support, raising the possibility of an early election. Critics, including the Canadian Chamber of Commerce, have raised concerns about the clarity of the bill and its potential impact on access to prescription drugs, arguing it may impose additional burdens on taxpayers. Canadians spent an estimated C$41 billion on prescription drugs last year, with a significant portion covered by private plans and out-of-pocket expenses.
- Canada has passed a bill to cover contraception and diabetes drug costs.
- The program aims to support those without drug plan coverage.
- Federal spending is expected to increase by C$1.9 billion over five years.
- Alberta and Quebec may opt-out of the program due to federal interference concerns.
- The legislation is linked to a deal between the Liberals and the NDP, which has since been withdrawn.
Related
Big Pharma claims lower prices means giving up miracle medications. Ignore them
Medicare's drug price negotiations starting January 2026 raise concerns about innovation in pharmaceuticals. However, studies show profitability remains high, and AI may enhance drug development despite lower prices.
FTC Accuses Drug Middlemen of Inflating Insulin Prices
The FTC is suing CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth’s Optum Rx for inflating insulin prices and harming consumers, amid increasing scrutiny of pharmacy benefit managers.
FTC Sues Prescription Drug Middlemen for Inflating Insulin Drug Price
The FTC has sued Caremark, Express Scripts, and Optum for anticompetitive practices inflating insulin prices, seeking to restore competition and potentially lower drug costs for consumers.
FTC sues insulin middlemen for pocketing billions while patients face high costs
The FTC has sued major pharmacy benefit managers for inflating insulin prices through a rebate system, leading to a 600% price increase over two decades, impacting diabetics' access to medication.
FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Prices
The FTC has sued Caremark, Express Scripts, and Optum for anticompetitive practices inflating insulin prices, targeting their rebate system and seeking to improve patient access to affordable medications.
1 commentsRelated
Big Pharma claims lower prices means giving up miracle medications. Ignore them
Medicare's drug price negotiations starting January 2026 raise concerns about innovation in pharmaceuticals. However, studies show profitability remains high, and AI may enhance drug development despite lower prices.
FTC Accuses Drug Middlemen of Inflating Insulin Prices
The FTC is suing CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth’s Optum Rx for inflating insulin prices and harming consumers, amid increasing scrutiny of pharmacy benefit managers.
FTC Sues Prescription Drug Middlemen for Inflating Insulin Drug Price
The FTC has sued Caremark, Express Scripts, and Optum for anticompetitive practices inflating insulin prices, seeking to restore competition and potentially lower drug costs for consumers.
FTC sues insulin middlemen for pocketing billions while patients face high costs
The FTC has sued major pharmacy benefit managers for inflating insulin prices through a rebate system, leading to a 600% price increase over two decades, impacting diabetics' access to medication.
FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Prices
The FTC has sued Caremark, Express Scripts, and Optum for anticompetitive practices inflating insulin prices, targeting their rebate system and seeking to improve patient access to affordable medications.